
Opinion|Videos|January 13, 2025
The Role of Posttransplant Cyclophosphamide in Patients With cGVHD
Author(s)Sergio A. Giralt, MD
Sergio A. Giralt, MD, discusses how he uses cyclophosphamide to treat patients with chronic graft-vs-host disease (cGVHD), particularly in specific cases where other therapies may not be effective. He reviews the study design and methods of recent research investigating cyclophosphamide in cGVHD management, emphasizing its importance in optimizing treatment strategies.
Advertisement
Video content above is prompted by the following:
- Which patients with chronic graft-vs-host disease (cGVHD) do you treat with cyclophosphamide in your clinical practice?
- What were this abstract’s study design and methods, and why was it important to investigate for cGVHD management?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Clascoterone 5% Delivers Strong Phase 3 Results for Androgenetic Alopecia
2
Bills to Address Expiring ACA Subsidies Fail to Pass Senate
3
Cardiotoxicity Remains a Concern as Breast Cancer Survival Rates Improve: Eric H. Yang, MD
4
Pirtobrutinib Outperforms Bendamustine-Rituximab in Frontline CLL/SLL
5








































